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We studied patients with acute myeloid leukemia (AML) over age 50 and in ﬁrst complete remission (CR1)
after adult unrelated donor (URD) (n ¼ 441, 8/8 HLA matched; n ¼ 94, 7/8 HLA matched) or umbilical cord
blood (UCB; n ¼ 205) transplantations. UCB recipients achieved CR1 within 8 weeks less often, and received
reduced-intensity conditioning and cyclosporine-based graft-versus-host disease (GVHD) prophylaxis more
often. Neutrophil recovery was slower in UCB (69% by day 28) compared with 8/8 HLA-matched URD (97%)
and 7/8 HLA-matched (91%) (P < .001) recipients. Three-year transplantation-related mortality (TRM) was
higher and leukemia-free survival (LFS) lower with UCB (35% and 28%, respectively) versus 8/8 HLA-
matched URD (27% and 39%, respectively). TRM was higher in 7/8 HLA-matched URD (41%, P ¼ .01), but
LFS was similar at 34% (P ¼ .39). Three-year chronic GVHD was the lowest in UCB (28%) versus 53% and 59%
in 8/8 and 7/8 HLA-matched URD recipients, respectively. Three-year survival was 43% in 8/8 HLA-matched
URD (95% conﬁdence interval [CI], 38% to 48%), 30% in UCB (95% CI, 23% to 37%) (P ¼ .002) and 37% in 7/8
URD (95% CI, 27 to 46). Allotransplantation for AML in CR1 with any of these grafts extends LFS for over one
third of older patients. In the absence of an 8/8 HLA-matched URD or when transplantation is needed
urgently, UCB can provide extended survival. Less frequent chronic GVHD with UCB transplantation may be
of particular value for older patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Postremission allogeneic transplantation is increasingly
used for treatment of the high-risk acute myeloid leukemia
(AML) affecting older adults [1-14]. Although previous
reports have validated the utility of several alternative donor
sources, little data exist to carefully examine differences in
toxicities, outcome, and potency of leukemia control
amongst the available donor choices in these patients.
Reports that have compared fully HLA-matched bone
marrow and peripheral blood progenitor cell trans-
plantations to mismatched umbilical cord blood (UCB)
transplantations conﬁrm comparable leukemia-free survival
between the 3 graft sources [15,16]. Transplantation-related
mortality (TRM) rates are higher and hematopoietic recov-
ery and chronic graft-versus-host disease (GVHD) are loweredgments on page 821.
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14.02.020after UCB compared with matched bone marrow and
peripheral blood progenitor cell transplantation. A limitation
of published reports is the inclusion of patients with both
acute myeloid and lymphoblastic leukemia and inclusion of
adults of all ages, with the median ages of study cohorts
ranging from 30 to 40 years. Data from the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR)
show 60% of allogeneic transplant recipients with hemato-
logic malignancies in the United States are now over the age
of 50. Because older adults (aged 50 years or older) have
healthy siblings available to be donors less frequently,
volunteer adult unrelated donors (URD) or umbilical cord
blood (UCB) grafts can facilitate the curative potential of
allotransplantation and to date, haploidentical trans-
plantations are rarely performed in this age group. Although
physicians may have little hesitation in recommending
HLA-matched sibling donor transplantation, higher GVHD
and mortality risks associated with unrelated donor (URD)
transplantation might limit others from offering this treat-
ment option for older adults [17-20]. As GVHD risks are high
after mismatched URD transplantation, there is furtherTransplantation.
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HLA-matched adult unrelated donor is not available. There-
fore, in the current analyses, we examined outcomes in 742
adults over the age of 50 years with AML in ﬁrst complete
remission (CR1) to compare the effectiveness of trans-
plantation of grafts from HLA-matched and mismatched
adult donors to that after HLA-mismatched UCB.
METHODS
Patients
Data were obtained from the CIBMTR or Eurocord. Included are alloge-
neic transplant recipients with AML in CR1, ages 50 years and older. Patient
characteristics and treatment details are summarized in Table 1. ThreeTable 1
Patient, Disease, and Transplantation Characteristics
Variables 8/8 HLA-Matched
No. of patients 441
Age, yr
Median (range) 58 (50-75)
50-60 263 (60%)
61-75 178 (40%)
Gender
Male 262 (59%)
Female 179 (41%)
CMV serostatus
Negative 172 (39%)
Positive 260 (59%)
Not reported 9 (2%)
WBC at diagnosis
<25  109/L 328 (74%)
25  109/L 82 (19%)
Not reported 31 (7%)
Time to achieve CR1
8 wk 307 (70%)
>8 wk 127 (29%)
Not reported 7 (2%)
Cytogenetic risk
Favorable 14 (3%)
Intermediate 154 (35%)
Unfavorable 133 (30%)
Conditioning regimen
Myeloablative
TBI þ other agents* 49 (11%)
Busulfan þ cyclophosphamide 78 (18%)
Busulfan þ ﬂudarabine 92 (21%)
Reduced-intensity
TBI 200 cGy þ cyclophosphamide þ ﬂudarabine 1 (<1%)
Fludarabine þ alkylating agent 188 (43%)
TBI 200 cGy þ ﬂudarabine 33 (7%)
GVHD prophylaxis
Tacrolimus þ mycophenolate 94 (21%)
Tacrolimus þ methotrexate 247 (56%)
Tacrolimus alone 36 (9%)
Cyclosporine þ mycophenolate 35 (8%)
Cyclosporine þ methotrexate 27 (6%)
Cyclosporine alone 2 (<1%)
In vivo T cell depletion
No 267 (61%)
Yes 174 (39%)
Not reported e
Graft type
Peripheral blood progenitor cells 377 (85%)
Bone marrow 64 (15%)
One cord blood unit e
Two cord blood units e
Transplantation period
2005-2007 249 (56%)
2008-2010 192 (44%)
Follow-up, median (range), mo 50 (3-86)
TBI indicates total body irradiation; CMV, cytomegalovirus; CR1, ﬁrst complete rem
Data presented are n (%) unless otherwise indicated.
* Other agents include the following:8/8 HLA-matched transplantations: cyclop
cyclophosphamide, n ¼ 6; busulfan, n ¼ 1; cord blood: cyclophosphamide, n ¼ 14treatment groups were created based on graft type and donor-recipient
HLA match. These include adult URD donor-recipient pairs matched at
HLA-A, -B, -C, -DRB1 at the allele-level (8/8matched), thosemismatched at a
single locus (7/8 matched), and UCB donor-recipient pairs with the majority
(96%) mismatched at 1 or 2 HLA loci. HLA matching between units and re-
cipients considered lower-resolution (antigen-level) match at HLA-A and -B
and allele-level at DRB1. Matching at HLA-C or allele-level HLA matching at
HLA-A and -B were not considered as these data were not available. HLA
match between UCB units (n ¼ 125) was not considered, as the sample size
prohibits exploring any affect on transplantation outcomes. Among the 535
recipients of adult donor grafts, 458 (86%) received peripheral blood pro-
genitor cells and the remaining 77 (14%), bonemarrow. Of the 205 recipients
of UCB grafts, 80 (39%) received 1 UCB unit and 125 (61%) received 2 units.
UCB transplantations with a single unit and 2 units were grouped together,
as reports have not shown signiﬁcant differences in survival [21].7/8 HLA-Matched Cord Blood P Value
94 205
.72
58 (50-72) 59 (50-71)
58 (62%) 117 (57%)
36 (38%) 88 (43%)
.05
53 (56%) 99 (48%)
41 (44%) 105 (52%)
.90
34 (36%) 72 (35%)
58 (62%) 128 (62%)
2 (2%) 2 (2%)
<.001
72 (77%) 129 (63%)
13 (14%) 38 (19%)
9 (10%) 38 (19%)
<.001
66 (70%) 105 (51%)
24 (26%) 68 (33%)
4 (4%) 32 (16%)
<.001
1 (1%) 5 (2%)
33 (35%) 95 (46%)
31 (33%) 76 (37%)
<.001
7 (7%) 18 (9%)
15 (16%) 10 (5%)
22 (23%) 14 (7%)
__ 137 (67%)
40 (43%) 23 (11%)
10 (11%) 3 (1%)
<.001
24 (26%) 30 (15%)
47 (50%) 4 (2%)
4 (4%) 12 (5%)
14 (15%) 149 (73%)
4 (4%) 2 (1%)
1 (1%) 1 (<1%)
<.001
47 (50%) 130 (63%)
47 (50%) 65 (32%)
e 10 (5%)
81 (86%) e
13 (14%) e
e 80 (39%)
e 125 (61%)
<.001
57 (61%) 42 (20%)
37 (39%) 163 (80%)
61 (3-91) 37 (3-85)
ission; GVHD, graft-versus-host disease.
hosphamide, n ¼ 48; melphalan, n ¼ 1; 7/8 HLA-matched transplantations:
; ﬂudarabine, n ¼ 1; etoposide, n ¼ 1; not reported, n ¼ 2.
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Donor Program approved this study.
Outcomes
Neutrophil recovery was deﬁned as achieving an absolute neutrophil
count  .5 109/L for 3 consecutive days and platelet recovery to 20  109/L
by day 90. Grade II to IV acute GVHD and chronic GVHDwere assigned using
standard criteria [22,23], as data to determine National Institutes of Health
chronic GVHD classiﬁcations were not available for most patients. TRM was
deﬁned as death occurring in the absence of leukemia relapse. Leukemia
relapse was deﬁned as molecular, cytogenetic, or morphologic evidence of
recurrence. Treatment failure was deﬁned as relapse or death from any
cause; the inverse of leukemia-free survival. Overall mortality was deﬁned
as death from any cause.
Statistical Analysis
We compared demographics, treatment characteristics, and outcomes
among the 3 treatment groups: 8/8 HLA-matched URD, 7/8 HLA-matched
URD, and mismatched UCB transplantations. Chi-square or the Wilcoxon
statistic was used to compare patient, disease, and transplantation charac-
teristics between the 3 treatment groups for categorical or continuous
variables, respectively. The probabilities of neutrophil recovery, acute and
chronic GVHD, TRM, and leukemia relapse were calculated using the
cumulative incidence estimator [24], and leukemia-free and overall survival
were calculated using the Kaplan and Meier estimator [25]. To study the
association between treatment groups and outcomes, multivariate Cox
regression models were built [26]. Results are expressed as hazard ratios
(HR). All P values are 2-sided and values  .05 were considered signiﬁcant.
Multivariate models were built using the forward step-wise selection
process considering variables shown in Table 1. The treatment group (8/8
HLA-matched URD, 7/8 HLA-matched URD, or UCB transplantation), as the
main study question, was included in all steps of model building, regardless
of level of signiﬁcance. The other variables tested were retained in the ﬁnal
multivariate model if the variable attained the level of signiﬁcance set for
these analyses. All models met the assumptions of proportionality, except
for TRM. Therefore, a time-dependent model was created for TRM and the
effects are shown as within 3 months after transplantation and beyond this
period. There were no ﬁrst order interactions. Analyses were done using SAS
(version 9.3, Cary, NC).RESULTS
Patients, Disease, and Transplantation Characteristics
Among the 441 8/8 HLA-matched URD, 94 7/8 HLA-
matched URD, and 205 UCB transplantations, the ages of
the patients at transplantationwere similar. Themedian ages
at transplantation were 58 years for URD recipients and
59 years for UCB. However, slightly more UCB recipients
were female and a smaller fraction had a lower white blood
count at diagnosis. Performance score at transplantationwas
not available for 89 (43%) UCB recipients. However, among
those for whom performance score was available, there were
no differences across the 3 treatment groups; 274 of 441
(62%) recipients of 8/8 HLA-matched URD, 60 of 94 (64%)
recipients of 7/8 HLA-matched URD, and 87 of 116 recipients
of UCB transplants reported scores of 90 or 100 (P ¼ .15). UCB
recipients were less likely to achieve CR1 within 8 weeks
from diagnosis. Recipients of 7/8 HLA-matched (22 of 94;
23%) transplants were more likely to have had myelodys-
plastic syndrome preceding AML compared with recipientsTable 2
Univariate Analysis
Outcomes 8/8 HLA-Matched,
Probability
(95% CI)
7/8 HLA-M
Probability
(95% CI)
Neutrophil recovery at day 28 97% (96-99) 91% (85-9
Platelet recovery to 20  109/L at day 90 91% (88-93) 89% (83-9
Acute GVHD grade II-IV at day100 36% (32-41) 44% (34-5
Chronic GVHD at 3 years 53% (48-58) 59% (49-6
GVHD indicates graft-versus-host disease.of 8/8 HLA-matched (70 of 441; 16%) and UCB (31 of 205;
15%) transplants (P ¼ .05). In a subset of patients (n ¼ 352;
transplantations between 2008 and 2010), data on chemo-
therapy delivered before transplantation were available. In
these patients, 119 of 192 (61%) recipients of 8/8 HLA-
matched, 25 of 37 (68%) recipients of 7/8 HLA-matched,
and 67 of 96 (70%) recipients of UCB transplants proceeded
to transplantation after induction therapy (P ¼ .12).
Approximately 45% of recipients of 8/8 HLA-matched and
UCB transplants received a single cycle of induction therapy
compared with 50% of recipients of 7/8 HLA-matched
transplants (P ¼ .94). Recipients of 8/8 HLA-matched
(175 of 441, 40%) and UCB (90 of 205, 44%) transplants
were more likely to proceed to transplantation within
3 months of achieving CR1, compared with recipients of 7/8
HLA-matched URD transplants (with 24 of 94, 26%)
(P< .001). Data on cytogenetic risk were not available for one
third of adult donor transplantations and 14% of UCB trans-
plantations. Among those for whom data were available,
unfavorable risk cytogenetics was equally likely across the 3
treatment groups: 37% among UCB recipients compared with
30% and 33% among matched and mismatched URD re-
cipients, respectively. There were differences between UCB
and URD transplantations with respect to transplantation
conditioning and GVHD prophylaxis. UCB recipients were
more likely to receive reduced-intensity conditioning (RIC),
whereas URD recipients were just as likely to receive mye-
loablative or RIC. The combination of low-dose (200 cGy)
total body irradiation with cyclophosphamide and ﬂudar-
abine was used exclusively for recipients of UCB grafts. On
the other hand, fewer than 10% of URD recipients received
total body irradiation 200 cGy and ﬂudarabine. Nearly one
half of all RIC URD transplantation patients received an
alkylating agent with ﬂudarabine. Tacrolimus-based GVHD
prophylaxis was used most often in the URD recipients, and
cyclosporine combinations were used more often for UCB.
In vivo T cell depletion using antithymocyte globulin or
alemtuzumab was used for a smaller fraction of the UCB
transplantations (32%) compared with the URD groups (39%
and 50%, after 8/8 and 7/8 HLA-matched transplantations,
respectively). Most URD transplant recipients received
ﬁlgrastim-mobilized peripheral blood progenitor cells (85%
and 86% for 8/8 and 7/8 HLA-matched transplants, respec-
tively). URD transplantations were initiated in the earlier
study years for this older age population and accounted for
56% of 8/8 URD and 61% of 7/8 URD transplantations between
2005 and 2007, whereas 80% of UCB transplantations were
performed between 2008 and 2010.Hematopoietic Recovery, GVHD, and TRM
After amedian follow-up of 50, 61, and 37months after 8/8
HLA-matched, 7/8 HLA-matched URD, and UCB trans-
plantations, respectively, univariate cumulative incidenceatched, Cord Blood,
Probability
(95% CI)
8/8 HLA-Matched
versus Cord Blood,
P Value
7/8 HLA-Matched
versus Cord Blood,
P Value
6) 69% (63-75) <.0001 <.0001
4) 69% (62-75) <.0001 <.0001
4) 35% (28-41) .69 .14
9) 28% (22-34) <.0001 <.0001
Table 3
Multivariate Analysis
Outcome Hazard Ratio
(95% conﬁdence interval)
P Value
Transplantation-related mortality
Early effect (0-3 months)
8/8 HLA-matched BM or PBPC 1.00
7/8 HLA-matched BM or PBPC 1.19 (.52-2.72) .68
Umbilical cord blood 2.83 (1.73-4.62) <.0001
Effect beyond 3 months
8/8 HLA-matched BM or PBPC 1.00
7/8 HLA-matched BM or PBPC 1.73 (1.18-2.54) .005
Umbilical cord blood 1.00 (.68-1.47) .99
Relapse*
8/8 HLA-matched BM or PBPC 1.00
7/8 HLA-matched BM or PBPC .86 (.57-1.29) .47
Umbilical cord blood 1.15 (.85-1.54) .36
Treatment failure*
8/8 HLA-matched BM or PBPC 1.00
7/8 HLA-matched BM or PBPC 1.18 (.91-1.53) .22
Umbilical cord blood 1.35 (1.09-1.65) .005
Overall mortalityy
8/8 HLA-matched BM or PBPC 1.00
7/8 HLA-matched BM or PBPC 1.24 (.95-1.62) .12
Umbilical cord blood 1.43 (1.16-1.76) .0008
BM indicates bone marrow; PBPC, peripheral blood progenitor cells.
* Adjusted for cytogenetic risk.
y Adjusted for cytogenetic risk and patient age.
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GVHDare shown inTable 2. Theprobabilities of hematopoietic
recovery were lower after UCB compared with 8/8 and 7/8
HLA-matched transplants (P < .0001). The probability of day-
100 grade II to IV acute GVHD, however, was similar in all 3
groups, but the 3-year probability of chronic GVHD was
signiﬁcantly lower after UCB transplantations compared with
8/8 and 7/8 HLA-matched transplantations (P < .0001).
Compared with that of 8/8 HLA-matched transplantations,
TRM was higher after 7/8 HLA-matched and UCB trans-
plantations (P ¼ .01 and P ¼ .05, respectively), but rates
were similar after UCB and 7/8HLA-matched transplantations
(P ¼ .42).
Results of multivariate analyses, adjusting for other
signiﬁcant factors showed that grade II to IV acute GVHD risksFigure 1. Treatment related mortality (*compared with 8/8 URD P < .0001 within 3 m
free survival, relapse, and survival after allogeneic HCT. Adjusted P values reﬂect the m
HLA-matched URD.were similar after UCB compared with 8/8 HLA-matched
transplantations (HR, .96; 95% conﬁdence interval [CI], .73 to
1.26; P ¼ .75). Acute GVHD risks were higher after 7/8
compared with 8/8 HLA-matched transplantation (HR, 1.46;
95% CI, 1.06 to 2.03; P ¼ .01). In vivo T cell depletion was
associated with signiﬁcantly lower risks of acute GVHD, in-
dependent of graft type (HR, .56; 95% CI, .43 to .72; P< .0001).
Compared with that of 8/8 HLA-matched transplantations,
chronic GVHD risks, analyzed with death as a competing
hazard, were signiﬁcantly lower after UCB transplantations
(HR, .49; 95% CI, .37 to .66; P < .0001), but risks were higher
after 7/8 HLA-matched transplantations (HR,1.38; 95% CI, 1.03
to 1.85; P ¼ .03). As with acute GVHD, in vivo T cell depletion
was associated with lower chronic GVHD risks (HR, .52; 95%
CI, .42 to .66; P < .0001).
TRM was high after both UCB and 7/8 HLA-matched
transplantations compared with 8/8 HLA-matched trans-
plantations, but the timing of mortality differed. As shown,
compared with TRM risks of 8/8 HLA-matched trans-
plantations, TRM risks were signiﬁcantly higher after UCB
transplantations within the ﬁrst 3 months after trans-
plantation (Table 3) and, after 7/8 HLA-matched trans-
plantations, beyond 3 months after transplantation (Table 3).
The 3-year probabilities of TRM after 8/8 HLA-matched and
UCB transplantations were 27% (95% CI, 23% to 31%) and 35%
(95% CI, 28% to 42%), respectively, P ¼ .05 (Figure 1). The
corresponding probability after 7/8 HLA-matched trans-
plantation was 41% (95% CI, 31% to 51%), P ¼ .01. There were
no signiﬁcant differences in TRM rates after 7/8 HLA-
matched and UCB transplantations (P ¼ .30). The time to
CR1 and time from diagnosis or from CR1 to hematopoietic
cell transplantation (HCT) were not signiﬁcantly associated
with TRM or other outcomes. To examine these inﬂuences
more fully, we reassessed the demographic and trans-
plantation characteristics of those patients surviving free of
leukemia at 3 months after transplantation. At that time
point, the surviving UCB recipients were slightly younger
(median age, 58 versus 60 years; P ¼ .01), but other clinical
and demographic characteristics were similar between those
who died of transplantation-related complications within
the ﬁrst 3 months and those who survived into the latteronths of HCT; compared with 7/8 URD P < .001 beyond 3 months), leukemia-
ultivariate analyses shown in Table 3. * indicates P < .0005 compared with 8/8
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time period differences in clinical characteristics of 8/8 and
7/8 HLA-matched transplant recipients. Thus, the excess
toxicities of UCB grafting apparent in these ﬁrst 3 post-
transplantation months were associated, in part, with
slower engraftment and greater risks of graft failure. The
higher TRM after 7/8 HLA-matched transplantations is
attributable to higher risks of GVHD and its associated
morbidity and mortality. In addition, we tested for the effect
of performance score on the subset of patients for whom
these datawere available; TRM risks were higher for patients
who reported performance scores of 80 or lower (HR, 1.45;
95% CI, 1.08 to 1.94; P ¼ .01).
Relapse, Leukemia-free, and Overall Survival
Relapse risks were not signiﬁcantly different between
the 3 treatment groups (Table 3). Cytogenetic risk group
and intensity of transplantation conditioning regimen
were the only 2 factors that inﬂuenced relapse risks and
these effects were independent of donor graft type.
Relapse risks were higher in patients with unfavorable
cytogenetic risk compared with intermediate cytogenetic
risk (HR, 1.89; 95% CI, 1.41 to 2.50; P < .0001) and good
cytogenetic risk (HR, 3.85; 95% CI, 1.25 to 12.5; P ¼ .02).
Relapse risks were higher after RIC compared with mye-
loablative regimens (HR, 1.36; 95% CI, 1.04 to 1.77; P ¼ .02).
White blood cell count at diagnosis was not associated
with leukemia relapse. The 3-year probabilities of relapse,
adjusted for cytogenetic risk and intensity of trans-
plantation conditioning regimens, were 35% (95% CI, 30%
to 40%) and 35% (95% CI, 28% to 41%) after 8/8 HLA-
matched and UCB transplantations, respectively (P ¼ .95),
(Figure 1). The corresponding probability after 7/8 HLA-
matched transplantations was 26% (95% CI, 18 to 35) and
not different from that after 8/8 HLA-matched (P¼ .09) and
UCB transplantations (P ¼ .13).
Treatment failure (relapse or death; inverse of leukemia-
free survival) and overall mortality were higher after UCB
transplantations compared with after 8/8 HLA-matched
transplantations (Table 3). Treatment failure and mortality
risks after UCB transplantations and 7/8 HLA-matched
transplantations were not signiﬁcantly different. Cytoge-
netic risk group and patient age inﬂuenced treatment failure
and mortality. Mortality risks were also associated with
performance score. These effects were independent of donor
graft type. Treatment failure was higher in patients with
unfavorable cytogenetic risk compared with those with
intermediate cytogenetic risk (HR, 1.49; 95% CI, 1.06 to 1.85;
P¼ .0001) and good cytogenetic risk (HR, 2.04; 95% CI, 1.06 to
3.85; P ¼ .03), and was also higher in patients ages 61 to 75,
(P ¼ .046) without a signiﬁcant interaction with graft source.
The 3-year probabilities of leukemia-free survival, adjusted
for cytogenetic risk and age, were 39% (95% CI, 34% to 43%)
and 28% (95% CI, 22% to 35%) after 8/8 HLA-matched and UCB
transplantations, respectively (P ¼ .01) (Figure 1). The cor-
responding probability after 7/8 HLA-matched trans-
plantations was 34% (95% CI, 24% to 43%) and not different
from that after 8/8 HLA-matched (P ¼ .32) or UCB trans-
plantations (P ¼ .39). Similarly, overall mortality was higher
in patients with unfavorable cytogenetic risk compared with
those with intermediate cytogenetic risk (HR, 1.47; 95% CI,
1.19 to 1.82; P ¼ .0001) and those with good cytogenetic risk
(HR, 2.04; 95% CI, 1.04 to 4.00; P ¼ .04). Mortality risks were
also higher in patients ages 61 to 75 years compared
with those ages 50 to 60 years (HR, 1.21; 95% CI, 1.01 to 1.45;P ¼ .038) with no interaction between age and graft source.
Poor performance score (80) was associated with higher
overall mortality (HR, 1.27; 95% CI, 1.03 to 1.57; P ¼ .026) and
was independent of graft source. The 3-year probabilities of
overall survival adjusted for cytogenetic risk and age
were 43% (95% CI, 38% to 48%) and 30% (95% CI, 23% to 37%)
after 8/8 HLA-matched and UCB transplantations, respec-
tively (P ¼ .002) (Figure 1). The corresponding probability
after 7/8 HLA-matched transplantations was 37% (95% CI, 27%
to 46%) and not different from that after 8/8 HLA-matched or
UCB transplantations (P ¼ .25).
As 60% of UCB transplantations infused 2 UCB units and,
in 40%, a single UCB unit, we examined whether trans-
plantation outcomes were comparable between the 2
groups. With the exception of higher TRM at 3-years after
transplantation of 2 UCB units (41%; 95% CI, 32% to 50%)
compared with 1 UCB unit (27%; 95% CI, 18% to 37%), P ¼ .04,
there were no signiﬁcant differences in relapse or overall
survival. The 3-year probabilities of relapse after trans-
plantation of 2 UCB units compared with 1 unit were 35%
(95% CI, 26% to 44%) and 48% (95% CI, 35% to 62%), respec-
tively, P ¼ .09. The corresponding probabilities of overall
survival were 28% (95% CI, 20% to 37%) and 25% (95% CI, 14%
to 38%), P ¼ .70.
We also tested for other factors that may potentially in-
ﬂuence survival after transplantation, including patient
cytomegalovirus seropositivity (HR, 1.01; 95% CI, .83 to 1.22;
P¼ .96), conditioning regimen intensity (HR, 1.04; 95% CI, .84
to 1.27; P ¼ .74), and transplantation of grafts from female
donors to male recipients compared with other gender
combinations (HR, .99; 95% CI, .77 to 1.28; P ¼ .97) and found
none. Mortality risks were lower, but not signiﬁcantly for
patients for whom the interval between achieving CR1 and
transplantation was longer than 3 months compared with
those who underwent transplantation within 3 months (HR,
.83; 95% CI, .68 to 1.01; P ¼ .06). The interval between CR1
and transplantation was forced into the ﬁnal model and the
results were consistent with that reported above (data not
shown).
DISCUSSION
These data examining a large group of alternative donor
transplantations in older patients reported to 2 large inter-
national observational registries demonstrate better out-
comes after 8/8 HLA-matched transplantations compared
with those after 7/8 HLA-matched URD or UCB trans-
plantations. These observations differ somewhat from those
previously reported from our groups as well as others [15-20].
The current analysis includes a homogenous group with AML
and all were in CR1 at transplantation, whereas other reports
included other leukemias and all disease stages at trans-
plantation. Our observations conﬁrm that, for the older pop-
ulation with AML, allotransplantation in CR1 can provide
extended leukemia-free survival for 30% to 43% of patients
using any of the donor graft sources available to them.
Although an 8/8 HLA-matched adult URD is preferred for
patients who can promptly obtain such a donor, there are
known limitations in timely donor availability. For those
ethnic or racial minorities, or mixed race populations where
suitably HLA-matched adult unrelated donors are uncom-
monly identiﬁed, banked unrelated UCB or adult URD mis-
matched at a single HLA-locus provide ameaningful chance of
extended leukemia-free survival [27-29]. The higher TRM
after mismatched transplantations with UCB and adult
URD must be considered when opting for a mismatched
D. Weisdorf et al. / Biol Blood Marrow Transplant 20 (2014) 816e822 821transplantation. Additionally, the rapid availability of UCB
units provides effective therapy for older patients with ex-
pected short initial remissions; settings where ongoing
consolidation therapy has not been effective in limiting risks
of relapse [28-36]. Another option of recent interest is a
haploidentical family donor, but as yet, it is uncommonly
chosen for this age group. During the study period (2005 to
2010), only 29 haploidentical HCTs for patients over age 50
with AML in CR1 were reported to the CIBMTR, precluding
meaningful analysis of this approach. Other factors, including
polymorphisms for immunologically or pharmacologically
relevant genetic elements, might also differentially inﬂuence
outcomes, but such data were not available for our analysis
[37-41].
Other factors may inﬂuence the choices of HCT using
different donors and grafts, particularly with broader and
extended experience in this older population; or affect the
choicewhether to proceed to HCTat all [42,43]. The generally
disappointing outcomes for older patients with AML treated
more conventionally cannot be compared directly in this
observational HCT dataset, though other reports have sug-
gested value for this allografting approach [3,5,7,17,27-29,31-
33]. Nonetheless, when considering HCT for older patients,
the signiﬁcantly lower risks of chronic GVHD, occurring
without apparent compromise in antileukemic protection,
might be associated with less morbidity and late mortality in
recipients of UCB transplants [9]. Avoiding the need for long-
term immunosuppression and its associated morbidities
may be of added importance for these older patients. An
additional study, directed towards the functional recovery
and quality of life of survivors after allotransplantation at 1, 2,
or more years beyond transplantation, may provide needed
insights in assessing these differential late morbidities of an
otherwise successful allograft [1]. Studies addressing func-
tional recovery and health-related quality of life are outside
the scope of registry-based studies such as ours.
Limited other data have described outcomes of alterna-
tive donor transplantation for this older population. In-
vestigators from the University of Minnesota in the United
States, Hôpital Saint-Louis, and Nantes in France recently
described similar overall and leukemia-free survival in a
modest-sized population of patients with AML in the same
age group [42]. These somewhat better, or at least compa-
rable outcomes, in these 3 experienced centers when judged
against this multicenter observational registry data may
reﬂect center experience in donor selection and speciﬁc
management practices for this older population and suggests
that specialized techniques may further improve the re-
ported outcomes for this older population. Earlier, McClune
et al. reported similar outcomes for a cohort of sibling and
URD recipients overlapping this age group, emphasizing that
allotransplantation is an appropriate and valuable alterna-
tive for patients with AML in early remission [44].
The current analysis was conducted using data collected
by 2 large international registries and subject to several
limitations. There were differences in patient and disease
characteristics, as well as in transplantation strategies, be-
tween the comparison groups, which were in part overcome
by performing carefully controlled regression analyses.
Further improvements in donor and graft selection to in-
crease the fraction with HLA-allele better-matched grafts,
improved HLA matching and cell dose for UCB unit selection,
plus elements of supportive care using in vivoTcell depletion
and optimal GVHD prophylaxis, could further improve sur-
vival for this older population. Although older patients withAML are often presumed to be too old or too sick for trans-
plantation and infrequently have available matched sibling
donors, these encouraging results suggest that allo-
transplantation need not be withheld, and for the right AML
patients, can produce extended and even curative long-term
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